Coverage
-
June 20, 2017
Staar Surgical Co., accused by investors of wrongly downplaying the U.S. Food and Drug Administration's concerns about its manufacturing practices, has reached a $7 million deal to end the litigation, according to a proposal filed in California federal court Tuesday.
3 other articles on this case.
View all »